NICU Adoption Prolacta’s 100% human milk-based fortifiers are trusted by more than 55% of Level 3&4 U.S. NICUs, indicating a large, established footprint with potential for upsell and expansion into remaining high-acuity NICUs.

Clinical Provenance With 30+ peer-reviewed studies showing shorter NICU stays and better outcomes for the smallest preemies, emphasize clinical value to drive conversations with neonatal directors and purchasing committees seeking data-driven ROI.

Surgifort Opportunity Surgifort is FDA-approved for term infants recovering from gastroschisis surgery, presenting a targeted cross-sell path to hospitals performing specialized pediatric surgeries and post-operative nutrition programs.

Expansion Catalysts Historical leadership hires and recent strategic roles suggest ongoing initiatives in education and business development; leverage new clinical education leadership to partner on training programs, protocols, and contract renewals.

Cost-Containment Angle Highlight potential hospital cost reductions through Exclusive Human Milk Diets, appealing to hospital CFOs and procurement through total-cost-of-care narratives tied to shorter stays and improved outcomes.